Skip to Main Content
Contribute Try STAT+ Today

Good morning, and a fine Friday to you from STAT reporter Andrew Joseph, here filling in for Mr. Pharmalot for the day. We’re one cup of stimulation in (this week’s bag of beans promises subtle notes of blackberry and citrus), and while we compile these items of interest, are dreaming of cup No. 2. While we may not have a campus we can claim as our own, the racket from the cranky radiator in our apartment is providing a different kind of ambiance. Wishing you all a restful weekend — perhaps even a celebratory one. We here at STAT yesterday marked the 6-year anniversary of our site going live, so cheers from us, and thanks for reading. …

An experimental antiviral pill developed by Pfizer (PFE) reduced the risk of death and hospitalization by 89% in patients who were newly diagnosed with Covid-19 in a large study, STAT reports. The development of oral medicines that can be used to treat Covid early on could blunt the impact of the pandemic, and Pfizer’s announcement follows reports from Merck (MRK) and its partner Ridgeback Therapeutics that their pill, molnupiravir, reduced hospitalization and death by 50%.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Create a display name to comment

This name will appear with your comment